Merrimack Pharmaceuticals Soars on Positive Pancreatic Cancer Study; LinkedIn Beats Analysts’ Forecasts

Follow this company

Companies Mentioned

05/02/2014 [ACCESSWIRE] Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) – For an in-depth report on Merrimack Pharmaceuticals, Inc. follow:   

Shares of MACK closed up nearly 60% on Thursday with about 30.1 million shares traded. The stock was one of the biggest gainers on the NASDAQ and hit a new yearly high of $7.65 during intra-day trading.  The company announced Thursday that patients treated with the company’s experimental pancreatic cancer drug lived longer than patients who received only standard chemotherapy.

MasterCard Incorporated (NYSE: MA) - For an in-depth report on MasterCard Incorporated follow: 

Shares of MasterCard barely closed in the green on Thursday with about 9.7 million shares traded. Despite the modest gain, the company posted that net income climbed 14 percent in the first quarter. The results exceeded Wall Street estimates.

LinkedIn Corporation (NYSE: LNKD) - For an in-depth report on LinkedIn Corporation follow:

Shares of LinkedIn Corporation closed up about 5% on Thursday and traded about 6.5 million shares. The stock was one of the most active stocks on the NYSE. Although the company posted a first-quarter loss, its financial results still surpassed analysts’ forecasts. The company lost $13.3 million, or 11 cents a share in the first quarter, compared with earnings of $22.6 million, or 20 cents a share, a year earlier.

MyECheck, Inc. (OTC: MYEC) - For an in-depth report on MyECheck, Inc. follow:

Shares of MYEC closed up nearly 19% on Thursday with about 37 million shares. The stock was one of the biggest gainers in the OTC market despite the company not releasing any significant news. The company operates as an electronic transaction data processor that provides an alternative payment solution to paper checks, payment cards, and automated clearing house payments in the United States.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 


Leave a comment...

Your Name